Be part of the knowledge.™

Rheumatology

66

LikeLikedUnlike

16-20 of 20

Can We Do Better in IgAN?
CME/CE
Can We Do Better in IgAN?
- Jonathan Barratt, PhD
  Peer
- Annette Bruchfeld, MD, PhD
  Peer
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
CME/CE
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
- Jonathan Barratt, PhD
  Peer
- Donald E. Kohan, MD, PhD
  Peer
Case-Based Management of AAV
CME/CE
Case-Based Management of AAV
- David Jayne, MD
  Peer
- Annette Bruchfeld, MD, PhD
  Peer
Updates in Glomerular Disease
CME/CE
Updates in Glomerular Disease
- Jürgen Floege, MD
  Peer
- Jonathan Barratt, PhD
  Peer
- David Jayne, MD
  Peer
Pinpointing the Top Questions about Biosimilars in Rheumatology
Rheumatology
Pinpointing the Top Questions about Biosimilars in Rheumatology
- Leonard H. Calabrese, DO
  Peer
- John R. Tesser, MD
  Peer
advertisement

Program Chapters

Segment Chapters

Playlist:

Recommended